岭南心血管病杂志
嶺南心血管病雜誌
령남심혈관병잡지
SOUTH CHINA JOURNAL OF CARDIOLOGY
2009年
3期
187-190,194
,共5页
普伐他汀%不稳定型心绞痛%妊娠相关蛋白-A%细胞因子
普伐他汀%不穩定型心絞痛%妊娠相關蛋白-A%細胞因子
보벌타정%불은정형심교통%임신상관단백-A%세포인자
pravastatin%unstable angina pectoris%pregnancy-associated plasma protein-A%cytokines
目的 探讨普伐他汀对不稳定型心绞痛患者血清妊娠相关蛋白-A(pregnancy-associated plasma protein-A,PAPP-A)和细胞因子的影响.方法 测定50例常规治疗组和50例普伐他汀治疗组不稳定型心绞痛患者治疗前后血清PAPP-A、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)、间质金属蛋白酶9(matrix metallopmteinases-9,MMP-9),以及低密度脂蛋白胆固醇(low-density lipoprotein,LDL-C)浓度,所得结果 进行统计分析.结果 普伐他汀组治疗12周后血清PAPP-A、TNF-α、IL-6、MMP-9及LDI-C浓度均较治疗前明显降低(P<0.05),而常规治疗组治疗前后血清PAPP-A、TNF-α、IL-6、MMP-9及LDI-C浓度差异无统计学意义(P>0.05).普伐他汀组血清PAPP-A、TNF-α、IL-6、MMP-9浓度和LDL-C浓度无相关性(r=0.10,P>0.05;r=0.02,P>0.05;r=0.08,P>0.05;r=0.05,P>0.05).结论 普伐他汀可以降低不稳定型心绞痛患者血清PAPP-A和细胞因子浓度,减轻炎症反应,稳定冠脉粥样硬化斑块,并且这种机制独立于降脂作用以外.
目的 探討普伐他汀對不穩定型心絞痛患者血清妊娠相關蛋白-A(pregnancy-associated plasma protein-A,PAPP-A)和細胞因子的影響.方法 測定50例常規治療組和50例普伐他汀治療組不穩定型心絞痛患者治療前後血清PAPP-A、腫瘤壞死因子-α(tumor necrosis factor-α,TNF-α)、白細胞介素-6(interleukin-6,IL-6)、間質金屬蛋白酶9(matrix metallopmteinases-9,MMP-9),以及低密度脂蛋白膽固醇(low-density lipoprotein,LDL-C)濃度,所得結果 進行統計分析.結果 普伐他汀組治療12週後血清PAPP-A、TNF-α、IL-6、MMP-9及LDI-C濃度均較治療前明顯降低(P<0.05),而常規治療組治療前後血清PAPP-A、TNF-α、IL-6、MMP-9及LDI-C濃度差異無統計學意義(P>0.05).普伐他汀組血清PAPP-A、TNF-α、IL-6、MMP-9濃度和LDL-C濃度無相關性(r=0.10,P>0.05;r=0.02,P>0.05;r=0.08,P>0.05;r=0.05,P>0.05).結論 普伐他汀可以降低不穩定型心絞痛患者血清PAPP-A和細胞因子濃度,減輕炎癥反應,穩定冠脈粥樣硬化斑塊,併且這種機製獨立于降脂作用以外.
목적 탐토보벌타정대불은정형심교통환자혈청임신상관단백-A(pregnancy-associated plasma protein-A,PAPP-A)화세포인자적영향.방법 측정50례상규치료조화50례보벌타정치료조불은정형심교통환자치료전후혈청PAPP-A、종류배사인자-α(tumor necrosis factor-α,TNF-α)、백세포개소-6(interleukin-6,IL-6)、간질금속단백매9(matrix metallopmteinases-9,MMP-9),이급저밀도지단백담고순(low-density lipoprotein,LDL-C)농도,소득결과 진행통계분석.결과 보벌타정조치료12주후혈청PAPP-A、TNF-α、IL-6、MMP-9급LDI-C농도균교치료전명현강저(P<0.05),이상규치료조치료전후혈청PAPP-A、TNF-α、IL-6、MMP-9급LDI-C농도차이무통계학의의(P>0.05).보벌타정조혈청PAPP-A、TNF-α、IL-6、MMP-9농도화LDL-C농도무상관성(r=0.10,P>0.05;r=0.02,P>0.05;r=0.08,P>0.05;r=0.05,P>0.05).결론 보벌타정가이강저불은정형심교통환자혈청PAPP-A화세포인자농도,감경염증반응,은정관맥죽양경화반괴,병차저충궤제독립우강지작용이외.
Objectives To investigate the effects of pravastatin on serum concentration of PAPP-A and cytokines in patients with unstable angina pectoris. Methods We measured the serum concentrations of pregnancy-associated plasma protein-A (PAPP-A), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), matrix metalloproteinases-9 (MMP-9) and low-density lipoprotein-C (LDL-C) before and after treatment in 50 cases of traditional treatment group and 50 cases of pravastatin group. Results Compared with before treatment, the serum concentrations of PAPP-A, TNF-α, IL-6, MMP-9 and LDL-C in pravastatin group significantly decreased after 12 weeks of treatment (P< 0.05). However, there was no significant difference between serum concentrations of PAPP-A, TNF-α, IL-6, MMP-9 and LDL-C in patients of traditional treatment group after and before treatment (P>0.05). There was no significant correlation between the serum concentrations of PAPP-A, TNF-α, IL-6, MMP-9 and the serum concentrations of LDL-C ( r=0.10, P>0.05; r =0.02, P>0.05; r=0.08, P>0.05; r=0.05, P>0.05) in pravastatin group. Conclusions Pravastatin can lower the serum concentrations of PAPP-A and cytokines in patients with unstable angina pectofis, restrains inflammation response, and stabilizes the coronary atherosclerusis plaque. The mechanism may be independent of the function of lowering cholesterol.
